{"id":"NCT00560417","sponsor":"Eli Lilly and Company","briefTitle":"Comparison of Two Basal Insulins for Patients With Type 2 Diabetes Taking Oral Diabetes Medicines and Exenatide","officialTitle":"A Randomized Trial Comparing Insulin Lispro Protamine Suspension With Insulin Glargine in Subjects With Type 2 Diabetes on Oral Antihyperglycemic Medications and Exenatide","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-11","primaryCompletion":"2009-12","completion":"2009-12","firstPosted":"2007-11-19","resultsPosted":"2010-12-14","lastUpdate":"2011-01-13"},"enrollment":339,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"Insulin Lispro Protamine Suspension","otherNames":["LY275585[P]"]},{"type":"DRUG","name":"Insulin Glargine","otherNames":["Lantus"]}],"arms":[{"label":"ILPS","type":"ACTIVE_COMPARATOR"},{"label":"Glargine","type":"ACTIVE_COMPARATOR"}],"summary":"This study will compare insulin lispro protamine suspension (ILPS) and insulin glargine in combination with the patient's oral diabetes medications and exenatide, for their ability to control blood sugar in patients with type 2 diabetes.","primaryOutcome":{"measure":"Change From Baseline in Hemoglobin A1C (HbA1c) at Endpoint (Last Observation Carried Forward [LOCF])","timeFrame":"Baseline, Endpoint (LOCF) up to 24 weeks","effectByArm":[{"arm":"ILPS","deltaMin":8.48,"sd":0.04},{"arm":"Glargine","deltaMin":8.47,"sd":0.04}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":52,"countries":["United States","Puerto Rico"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":170},"commonTop":["Headache","Diarrhoea","Nausea","Nasopharyngitis","Upper respiratory tract infection"]}}